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A variety of topical depigmenting agents have been used clinically, with varying degrees of success. To
date, the most effective topical treatment is a triple-combination agent containing hydroquinone (HQ),
tretinoin, and ﬂuocinolone acetonide. However, its use is associated with relatively high frequencies of
adverse reactions, and therefore there is a necessity to produce effective topical depigmenting agents
with fewer adverse effects. Several processes can be targeted for the treatment of hyperpigmentation;
speciﬁcally, regulation of melanogenesis by inhibiting tyrosinase activity, a key enzyme in melanin
synthesis, represents a major therapeutic target. Another option is regulation of melanosomes by
manipulation of their formation or transfer. In addition, depigmenting agents can act through antioxi-
dant or anti-inﬂammatory activities. We compared the tyrosinase inhibitory activity and cytotoxicity of
HQ with those of other cosmetic ingredients. The results showed that although HQ was a strong
tyrosinase inhibitor, it was cytotoxic at high concentrations. By contrast, 4-n-butylresorcinol effectively
controlled tyrosinase activity without showing toxicity at high concentrations. These ﬁndings indicated
that 4-n-butylresorcinol had the potential to act as an effective depigmenting agent, while producing less
irritation than the currently available agents.
Copyright © 2014, Taiwanese Dermatological Association.
Published by Elsevier Taiwan LLC. All rights reserved.Introduction
Recently, many topical depigmenting agents have been developed
and widely applied for the amelioration of pigmentary dermatoses.
Depigmenting formulations can be classiﬁed as either pharmaco-
logical agents or cosmetic agents. Hydroquinone (HQ) is a main
component of topical pharmacological agents, which exhibits great
efﬁcacy, but has a relatively high rate of adverse side effect.1e4 For
this reason, most of these formulations require a doctor's pre-
scription. By contrast, cosmetic agents place more importance on
safety, and therefore reduce adverse reactions by using nonirritant
ingredients or using lower concentrations of irritant ingredients.
Although these cosmetic agents can be used safely without a pre-
scription, they are generally less effective than HQ-based pharma-
cological agents. The present article reviews current clinical usage
of pharmacological and cosmetic depigmenting agents, as well as
the current status of emerging depigmenting ingredients. Iny have no ﬁnancial or non-
tter or materials discussed in
gy, Seoul National University
am-si, Gyeonggi-do 463-707,
cal Association. Published by Elsevaddition, we present laboratory data on the efﬁcacy and safety of
HQ and other cosmetic ingredients.
Pharmacological depigmenting agents
1,4-dihydroxybenzene (commonly known as HQ)
Most pharmacological depigmenting agents target the activity of
tyrosinase, a key enzyme in melanin synthesis. Tyrosinase is a
copper-containing transmembrane glycoprotein that is the rate-
limiting enzyme in melanogenesis.5 HQ, a powerful tyrosinase in-
hibitor, is the most extensively investigated antimelanogenic
agent.6,7 HQ competes with the tyrosinase substrate (i.e., tyrosine)
and prevents its enzymatic oxidation to dihydroxyphenylalanine. In
addition, oxidative products of HQ cause oxidative damage to
membrane lipids and proteins, including tyrosinase.8 In a ran-
domized, double-blind, placebo-controlled trial, Ennes et al9 re-
ported that 38% of patients treated with 4% HQ achieved clinical
clearance of melasma in 12 weeks, compared with only 8% of pa-
tients in the control group (Table 1). In another randomized,
double-blind trial, Haddad et al4 compared the efﬁcacy of 4% topical
HQwith a skin-whitening complex consisting of Arctostaphylos uva-
ursi, biofermented Aspergillus, grapefruit extract, and rice extract in
30 patients with melasma. HQ showed a 77% improvement,ier Taiwan LLC. All rights reserved.
Table 1 Summary of efﬁcacy and safety of topical depigmenting agents.
Topical agent Study Efﬁcacy Safety
Hydroquinone (HQ) 1998, Amer and
Metwalli2
“Good” to “excellent” response in 89.5%, 75%, and 44.4% of
patients with melasma, postinﬂammatory
hyperpigmentation, and freckles, respectively
Local irritation was noted in most patients
2003, Haddad et al4 76.9% of patients with melasma showed improvement 25% of patients experienced adverse events
2000, Ennes et al9 38.1% of the melasma patients showed total improvement,
57.2% showed partial improvement
28.6% of patients reported adverse events
Tretinoin 1993, Grifﬁths et al12 “Improved” or “much improved” in 68% of patients with
melasma
Moderate cutaneous side effects occurred in 88% of patients
1994, Kimbrough-
Green et al13
“Improved” in 32% or melasma patients Mild retinoid dermatitis occurred in 67% of patients
Triple-combination
cream (TCC)a
2003, Taylor et al20 75% reduction in >70% of patients with melasma 63% of patients experienced adverse events such as
erythema and desquamation
2005, Torok et al19 “Completely” or “nearly completely” cleared in >90% of
patients with melasma
57% of patients experienced adverse reaction
2007, Ferreira
Cestari et al18
Improvement of >75% was achieved in 73% of melasma
patients using TCC, whereas improvement (>75%) was
achieved in only 49% of patients using HQ
No signiﬁcant difference between the incidence of adverse
events in these two groups (15% in TCC vs. 9% in HQ)
2008, Chan et al21 “Cleared” or “signiﬁcantly improved” in 49.6% of patients
with melasma
48.8% of patients had related adverse events
Arbutin 2008, Ertam et al24 All of 10 melasma patients showed a signiﬁcant decrease of
melanin level
No side effects were observed
Azelaic acid 1991, Bali~na and
Graupe25
64.8% of melasma patients achieved a “good” or “excellent”
result
Local irritation was reported in 11.0% of patients
Kojic acid 2013, Monteiro et al27 Mean Melasma Area and Severity Index score was
decreased by 2.403 after 12 wks of application
One patient (3.3%) experienced erythema and burning
sensation
4-n-butylresorcinol 2010, Huh et al29 Mean melanin index was decreased by 4.87% after 8 wks of
application
No adverse events were observed after 8 wks
2010, Huh et al30 Mean melanin index was decreased by 7.51% after 8 wks of
application
No adverse events were observed throughout the study
a Combination of 4% HQ, 0.05% tretinoin, and 0.01% ﬂuocinolone acetonide.
J.W. Shin, K.C. Park / Dermatologica Sinica 32 (2014) 205e210206whereas the skin-whitening complex showed a 67% improvement
(Table 1).
Although HQ is proven to be a highly effective depigmenting
agent, the safety issue is still controversial. Amer and Metwalli2
demonstrated that HQ had a “good” to “excellent” effect on
melasma and postinﬂammatory hyperpigmentation, but most
participants experienced skin irritation (Table 1). In addition,
Haddad et al4 reported that 25% of patients treated with HQ
reported itchy eruption, whereas none of the patients treated
with the skin-whitening complex reported any side effects
(Table 1). Although themost common adverse events associated
with HQ usage in these investigations were mild and tolerable,
the use of topical medicationwith such a high rate of side effects
is burdensome for patients, especially in cosmetic conditions.
Furthermore, some rare but serious side effects have also been
reported with HQ use, such as exogenous ochronosis and per-
manent depigmentation. Exogenous ochronosis was caused by
the accumulation of homogentisic acid in the dermis, resulting
in degeneration of collagen and elastic ﬁbers, followed by the
irreversible deposition of ochre-colored ﬁbers.7 Permanent
depigmentation can be triggered by the destruction of mela-
nocytes after prolonged use of HQ.10 Considering these possible
long-term complications, the European Committee (24th
Directive 2000/6/EC) banned the use of HQ.6 However, Nor-
dlund et al11 reviewed the evidence related to the safe use of HQ
in 2006 and concluded that it was reasonable to use HQ for the
treatment of hyperpigmentation.
Tretinoin
Tretinoin is another topical pharmacological agent that acts by
inhibiting the activity of tyrosinase. This topical retinoid was ﬁrst
used in combination with HQ to enhance its penetration; however,
it was later recognized that retinoid alone has an effect on
pigmentation by inhibiting the activities of tyrosinase anddopachrome conversion factor.1 Concentrations ranging from
0.025% to 0.1% have been used to treat pigmentation disorders and
skin aging. In 1993, a randomized controlled trial evaluating the
efﬁcacy of topical 0.1% tretinoin was conducted in patients with
melasma by Grifﬁths et al (Table 1).12 After 40 weeks of using
tretinoin, 68% of the patients were rated as “much improved” or
“improved”, whereas only 5% of the vehicle group showed
“improvement”. However, the rate of adverse reaction was also
high in the study groups. Moderate cutaneous adverse effects (er-
ythema and irritation) occurred in 88% of patients in the tretinoin
group and in 29% of the vehicle group. In another study performed
by Kimbrough-Green et al,13 tretinoin also exhibited good clinical
efﬁcacy with a high rate of adverse events (Table 1). Moreover, a
review article by Kang et al14 reported that topical retinoids were
effective for the treatment of pigmentary disorders, either as
monotherapy or in combination with other topical agents.
Triple-combination cream
Triple-combination cream (TCC), which contains 4% HQ, 0.05%
tretinoin, and 0.01% ﬂuocinolone acetonide, is the most effective
topical treatment for melasma reported to date. TCC is the only HQ-
containing drug approved by the United States Food and Drug
Administration for the treatment of melasma.1,15 As mentioned
earlier, HQ and tretinoin show depigmenting effects by inhibiting
the activity of tyrosinase. Fluocinolone acetonide is a corticosteroid
that reduces levels of cytokines, including endothelin-1 and gran-
ulocyteemacrophage colony-stimulating factor, which mediate
UV-induced pigmentation.16,17 Apart from their individual depig-
menting effects, each ingredient of the TCC can help in reducing the
potential side effects of the other ingredients. Steroids reduce the
irritation caused by HQ, and tretinoin ameliorates corticosteroid-
induced epidermal thinning.15
Ferreira Cestari et al18 demonstrated that TCC was more effec-
tive than 4% HQ for the treatment of melasma (Table 1). In that
study, clearance of melasma lesions was observed in 35% of the
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HQ group. The incidence of adverse events, including erythema,
burning sensations, and desquamation, was similar in both study
groups. Although TCC treatment has been reported to show a high
efﬁcacy in many clinical studies, it is also associated with high rates
of adverse reactions. Torok et al19 reported that >90% of 173 pa-
tients studied experienced “complete” or “nearly complete” clear-
ance of melasma after a 12-month treatment with TCC. However,
129 patients (57%) experienced at least one treatment-related
adverse reaction, although these were generally mild and tran-
sient in nature (Table 1).18 In another investigation, Taylor et al20
also demonstrated high efﬁcacy and a high rate of adverse events
in patients treated with TCC (Table 1).
Asian patients have been reported to have a high potential
for skin irritation. A clinical trial was therefore conducted
to determine the efﬁcacy and safety of TCC in Asian patients. The
results of the clinical trial revealed that TCC effectively improved
melasma but had a considerable rate of adverse events (Table 1).21
Interestingly, Asian patients reported more symptomatic com-
plaints, such as skin discomfort or irritation, than did individuals
with other skin types.
In conclusion, although pharmacological depigmenting agents
such as HQ cream, tretinoin cream, and TCC have been shown to be
effective for the treatment of hyperpigmentation, adverse reactions
are common. These adverse reactions were mild and transient in
most cases, but a high rate of adverse effects may reduce patient
compliance and satisfaction. Thus, effective topical agents with
fewer adverse effects are urgently needed.Cosmetic depigmenting agents
Regulation of melanogenesis by controlling tyrosinase activity
This section considers cosmetic depigmenting agents that inhibit
tyrosinase activity, and classiﬁes them by their mechanism of ac-
tion (Table 2).Inhibition of tyrosinase activity
Arbutin, derived from the bearberry plant, is a naturally occurring
HQ beta-D-glucopyranoside. It is commonly used in the production
of cosmetic agents and is known to exhibit depigmenting activity at
nontoxic concentrations.22 Arbutin has been demonstrated to
suppress tyrosinase activity without affecting its messenger RNA
expression, and to inhibit 5,6-dihydroxyindole-2-carboxylic acidTable 2 Classiﬁcation of cosmetic depigmenting agents based on their mechanisms.






























Phospholipase D2(DHICA) polymerase activity.23 In a randomized, open-label study
conducted by Ertam et al,24 melanin level was signiﬁcantly
decreased in 10 melasma patients treated with 1% arbutin for 6
months.
Azelaic acid is a naturally derived dicarboxylic acid present in
Malassezia furfur. It inhibits tyrosinase activity, leading to the
hypopigmented macules commonly observed in tinea versicolor.
Bali~na and Graupe25 compared the efﬁcacy of 20% azelaic acid and
HQ in the treatment of melasma. In that 24-week trial, 64.8% of
patients treated with azelaic acid exhibited “good” or “excellent”
results, whereas 72.5% of patients treated with 4% HQ also reported
the same results. Thus, it was concluded that there was no signif-
icant difference in efﬁcacy between these two treatments, and se-
vere side effects (e.g., allergic sensitization or exogenous
ochronosis) were not observed with azelaic acid.
Kojic acid [5-hydroxy-2-(hydroxymethyl)-4-pyrone], an antibi-
otic produced by species of Aspergillus and Penicillium, produces
bleaching by chelating the copper in tyrosinase and inhibiting
nuclear factor-kB (NF-kB) activity in keratinocytes.26 Monteiro
et al27 compared the efﬁcacy of 4% HQ and 0.75% kojic acid cream
(including 2.5% vitamin C) in the treatment of melasma. After 12
weeks, the mean Melasma Area and Severity Index score was
decreased to 2.403 in the kojic acid group, whereas it was 11.423 in
the HQ group. These ﬁndings indicated that the 4% HQ cream is a
more effective topical depigmenting agent, with a rapid rate of
clinical improvement, when compared with the 0.75% kojic acid
cream.
4-n-Butylresorcinol also directly inhibits the activities of tyros-
inase and tyrosinase-related protein-1 (TRP-1).28 We have
demonstrated the efﬁcacy of this compound in several previous
clinical trials.29,30 In a randomized controlled split-face trial, 0.1% 4-
n-butylresorcinol cream showed rapid efﬁcacy with excellent
tolerability in patients with melasma (Table 1).29 In another ran-
domized, double-blind, vehicle-controlled, split-face study,
liposome-encapsulated 4-n-butylresorcinol had signiﬁcantly
reduced the melanin index after 8 weeks of application, without
any occurrence of adverse events (Figure 1 and Table 1).30
Reduction of tyrosinase production
Microphthalmia transcription factor (MITF) is a key factor con-
trolling the transcription of tyrosinase and TRP-1 genes.31 It is
crucial for both melanocyte proliferation and melanogenesis. Mu-
tations in human MITF result in hypopigmentation and deafness in
type 2A Waardenburg syndrome.5 Sphingosine-1-phosphate sus-
tains extracellular signal-regulated kinase (ERK) activation, and
induces MITF phosphorylation and degradation, which are
responsible for reducing melanin synthesis.32 Transforming growth
factor-b1 also induces signiﬁcant delay in ERK activation and ERK-
induced MITF downregulation, which could contribute to hypo-
pigmentation.33 We found that lysophosphatidic acid and C2
ceramides could induceMITF degradation or block MITF expression
through an initial effect on Akt/protein kinase B or ERK.34,35We also
found that another signaling lipid mediator, sphingosylphosphor-
ylcholine, may inhibit melanogenesis by transcriptional regulation
of the tyrosinase gene.36
Increase of tyrosinase degradation
Several topical fatty acids including linolenic, linoleic, and oleic
acids showed a depigmenting effect on guinea pig skin after UV
irradiation.37 The bleaching effects of these compounds may be due
to their stimulation of tyrosinase ubiquitination and proteasomal
degradation, because they did not inﬂuence the number of mela-
nosomes or the level of tyrosinase expression.38 Phospholipase D2,
an unsaturated fatty acid, also reduces melanogenesis through a
similar mechanism.39
Table 3 Tyrosinase activity in normal human melanocytes.
Hydroquinone Azelaic acid
1mM 10 mM 100 mM 1mM 10 mM 100 mM
Protein concentrationa 86.7 74.1 70.9 94.5 90.8 83.4
Tyrosinase activityb 65.7 68.1 35 91.5 100 106.2
Arbutin Kojic acid
1mM 10 mM 100 mM 1mM 10 mM 100 mM
Protein concentrationa 109.6 109.8 114.5 110.2 98.3 113.9
Tyrosinase activityb 88.8 78.8 63.7 94.8 95.3 84.9
Ascorbic acid L-glutathione
1mM 10 mM 100 mM 1mM 10 mM 100 mM
Protein concentrationa 105.1 105.6 96.4 90.8 98.5 101.4
Tyrosinase activityb 93.1 89.8 97.1 97.1 105.3 98.2
Hinokitiol 4-n-butylresorcinol
1mM 10 mM 100 mM 1mM 10 mM 100 mM
Protein concentrationa 93.7 84.6 77.2 119.0 116.0 118.6
Tyrosinase activityb 87 63.7 30.7 49.7 34.5 26.2
a % of control by Bradford assay
b % of control.
Figure 1 Clinical photographs of a patient treated with 0.1% 4-n-butylresorcinol cream, showing decreasing pigmentation over time: (A) before treatment; (B) after treatment for 4
weeks; (C) after treatment for 8 weeks. Note. From “The efﬁcacy and safety of 4-n-butylresorcinol 0.1% cream for the treatment of melasma: a randomized controlled split-face trial”
by S.Y. Huh, J.W. Shin, J.I. Na, C.H. Huh, S.W. Youn, and K.C. Park, 2010, Ann Dermatol, 22, p. 21e5. Copyright 2010, Annals of Dermatology. Adapted with permission.
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Melanosomes are specialized subcellular organelles in which
melanin is synthesized and deposited. A reduction in the transfer of
melanosomes from melanocytes to keratinocytes results in hypo-
pigmentation, as it blocks the dispersion of pigment to keratino-
cytes. Serine protease inhibition results in impaired activation of
protease-activated receptor 2 in keratinocytes, resulting in the
accumulation of melanosomes within melanocytes.40 In a previous
study, centaureidine (a ﬂavonoid glucoside isolated from yarrow)
and niacinamide (vitamin B3) were demonstrated to inhibit mela-
nosome transfer to keratinocytes (Table 2).41 Furthermore, glyco-
sylated residues on melanocyte and keratinocyte membranes are
critical for receptor-mediated endocytosis, and thus for facilitating
melanosome transfer. Lectins and neoglycoproteins have also been
shown to inhibit melanosome transfer (Table 2).42
Antioxidants
Compounds with antioxidant properties exhibit hypopigmenting
effects by interacting with o-quinones or copper at the active site of
tyrosinase, thus reducing the oxidative polymerization of melanin
intermediates. Moreover, antioxidant agents regulate the signaling
process enabling stimulation of epidermal melanogenesis, by
scavenging reactive oxygen species generated in the skin after UV
exposure.43 Cosmetic depigmenting agents that act through anti-
oxidant properties are summarized in Table 2.
Ascorbic acid interferes with different steps involved in melanin
production by interacting with copper ions, reducing dopaquinone,
and by blocking the oxidation of DHICA.44
a-Tocopherol and its derivative, a-tocopherol ferulate, interfere
with membrane lipid peroxidation and increase intracellular
glutathione content, thus leading to depigmentation.45
6-Hydroxy-3,4-dihydrocoumarins are novel antioxidants
recently reported to exert antimelanogenic effects in cultured hu-
man melanocytes at noncytotoxic concentrations.46 These com-
pounds might act by accelerating glutathione synthesis and
inhibiting tyrosinase transfer.47
Thioctic acid (a-lipoic acid), a disulﬁde derivative of octanoic
acid, has been reported to prevent UV-induced oxidative damage,
mainly by the downmodulation of NF-kB activation. It is also
known to inhibit tyrosinase activity, probably by copper ion
chelation.48
Resveratrol, a natural extract derived from the roots of Fallopia
japonica, has strong antioxidant properties. We performed a clinical
trial to evaluate the efﬁcacy of a whitening agent containing 0.05%
resveratrol. A total of 30 patients applied the agent twice daily and
signiﬁcant improvements were observed in the melanin index and
in clinical photographic assessments after 8 weeks (p < 0.05, un-
published data).Comparative laboratory study of HQ and cosmetic ingredients
Speculation on depigmenting agents
Whenpreparing topical drugs for pigmentary disorders, HQ is often
used as the main ingredient to inhibit tyrosinase activity. Although
HQ is a potent tyrosinase inhibitor, frequent adverse effects present
a major drawback in clinical practice. In the cosmetic industry,
many agents have been used to produce depigmenting cosmetics.
Because these agents are used at low and safe concentrations, their
efﬁcacy has not been extensively compared with that of HQ. A
comparative study is therefore necessary to develop effective and
safe topical agents for the treatment of pigmentary disorders.
Comparison of the efﬁcacy of HQ and other ingredients
commonly used to make cosmetics
We compared the tyrosinase-inhibition activities of various
depigmenting compounds using cultured normal human melano-
cytes (Table 3). At 100 mM, HQ inhibited the tyrosinase activity of
normal human melanocytes by 65%. However, protein concentra-
tions also decreased in a dose-dependent manner and reached
70.9% of the control level at 100 mM HQ (Table 3). These results
suggest that HQ is an effective tyrosinase inhibitor while also being
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adverse effects are so commonly observed with HQ-containing
formulations. In the cosmetic market, azelaic acid, arbutin, and
kojic acid are frequently used to produce depigmenting products.
Our results indicated that these agents did not show cytotoxicity at
high concentrations, but neither did they produce signiﬁcant
tyrosinase inhibition. This means that although they are relatively
safe, they may lack signiﬁcant depigmenting effects. Nevertheless,
because their cytotoxicity is very low, azelaic acid, arbutin, and
kojic acid can be used at high concentrations to achieve depig-
menting effects. As mentioned earlier, antioxidants may theoreti-
cally be used to prepare good depigmenting agents. However, our
results showed that ascorbic acid and L-glutathione did not signif-
icantly inhibit tyrosinase activity (Table 3). By contrast, hinokitiol
and 4-n-butylresorcinol effectively inhibited tyrosinase activity
(Table 3). Although hinokitiol decreased protein levels at high
concentrations, 4-n-butylresorcinol did not affect the protein
levels, even at 100 mMconcentrations. These ﬁndings indicated that
4-n-butylresorcinol can be used as an effective depigmenting agent
with an excellent safety proﬁle.
New approaches to developing depigmenting agents
The data described herein indicate that HQ is not a safe tyrosinase
inhibitor and that it is necessary to develop novel topical agents for
the treatment of pigmentary disorders. 4-n-Butylresorcinol may be
used to produce a safe cosmetic agent, with the clinical efﬁcacy
required of a pharmacological agent. Furthermore, a multitarget
approach is necessary because the combined use of two agents
with different mechanisms of action can produce more powerful,
additive effects. For example, 4-n-butylresorcinol acts mainly by
inhibition of tyrosinase activity and has no effect onMITF. However,
when combined with hinokitiol, an additive effect is produced
which reduces MITF expression.5,28 The combination of two agents
with different mechanisms may therefore be another useful strat-
egy for increasing the efﬁcacy of these agents.
Conclusion
Although HQ ismost commonly used to treat pigmentary disorders,
a literature review and our laboratory results strongly suggested
that new topical pharmaceutical depigmenting agents are required
to enable safer and more effective treatment of pigmentary
disorders.
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